Market Highlights

Following a careful analysis of the latest Drug Device Combination Market trends, Market Research Future (MRFR) in its latest report states that the Drug Device Combination Market is expected to reach USD 251.90 Billion by 2030 at 7.2% CAGR during the forecast period 2022-2030.

Companies Profiled

The leading participants in the worldwide Drug Device Combination Market Players are

Abbott Laboratories, AlloSource, Biomet Orthopedics, Inc., Wright Medical Group, Inc., Biotronik, Boston Scientific Corporation, St. Jude Medical Inc, 3M Inc., Covidien Ltd, Biometrix Medical, Stryker Corporation, C.R. BARD, Zimmer Holding, Inc., Cook Critical Care, Inc., Smith & Nephew Plc

Growth Drivers and Top Barriers

drug device combination products allows early diagnosis along with shorter treatment duration in most of the surgical procedures. The surge in the demand is also the result of various other benefits including minimal pain, improved safety, cost efficiency, high efficacy, speedy recovery, and decreased hospital stay owing to these devices. The growing number of regulatory healthcare authorities defining the strict protocols for premarket authorizations is projected to prompt the manufacturers in getting approvals for their products. For instance, the United States (U.S.) FDA had come up with the lean management process mapping approach for developing a more streamlined, cohesive, collaborative and systematic system to analyze the said products. The stringent safety guidelines as well as recommendations by the authorities across the globe are poised to raise the adoption rate of these products in the coming years, stimulating the growth of the overall market.

Market Segmentation

The worldwide Drug Device Combination Market has been segmented on the basis of product, application, and end user.

·         In terms of product, the market can be broken down into catheter, advanced wound care products, and others.

·         Application-wise segments in the market are coronary angioplasty, tachycardia management, non-cardiovascular treatments, peripheral arterial disease (pad), bone treatment, antimicrobial applications, wound care, ophthalmic treatment, and others.

·         The end users covered in the report include hospitals & clinics, ambulatory centers, and academic & research organization, and others.

Regional Segmentation

The Americas, Europe, Asia Pacific and the Middle East & Africa are the key regions in the global drug device combination market.

The Americas has left other regions in the lurch with the dominant share of the overall market, due to the growing prevalence of cardiovascular diseases coupled with the existence of prominent players based in the region. Moreover, appropriate reimbursement policies, elevated spending on healthcare, and a well-established healthcare industry in the United States (U.S.) and Canada are identified as the crucial drivers for the drug device combination market in the region.

The data experts report that Europe had been at the second position in the global drug device combination market in 2017, with factors like the presence of a highly-developed healthcare infrastructure, surging awareness about the devices and the massive contribution of developed nations in the region backing the market growth. On top of that, a humungous patient pool is powering the regional market further.

Expanding at the fastest growth rate as reported in 2017, Asia Pacific is launching ahead backed by the growing penetration of prominent vendors into the region, booming healthcare sector and rising support of the government for foreign investments. A report furnished by the Indian Brand Equity Foundation in 2017 states that the Indian healthcare industry was predicted to expand at a CAGR of 22.87, with further predictions of it set to reach the valuation of USD 280 billion by the year 2020. These favorable numbers are expected to subsequently work in favor of the drug device combination market in the following years.

Finally, the Middle East and Africa accounts for the smallest in the worldwide drug device combination market share because of the presence of poor countries as well as low per capita income, particularly in the Africa region. The regional market is forecasted to be governed by the Middle East as a result of the growing government funding in a bid to expand the healthcare industry, in addition to the presence of flourishing nations such as the United Arab Emirates, Dubai, Saudi Arabia, among others.

Industry News

May 2019: Medtronic PLC MDT has recently launched the Telescope guide extension catheter that will offer support as well as access to the distal lesions. This product launch reflects the company’s entry marks the company’s entry into the guide extension catheter market and subsequently the drug device combination market.

Related Report-

https://www.pickmemo.com/read-blog/110759

https://www.linkedin.com/pulse/whole-exome-sequencing-market-set-exhibit-strong-growth-arpita-gupta-1c

About US:

Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013